(AOF) – Abionyx Pharma records consolidated turnover of 4.64 million euros for the 2023 financial year compared to 5.25 million euros in 2022. Its cash position amounts to 4.1 million euros as of December 31, 2023 compared to 4.04 million euros in 2022. Concerning the biotech activity dedicated to the discovery and development of innovative therapies aimed at improving the lives of patients, the company did not generate any turnover on this exercise.
The company recalls that beyond available cash of 4.1 million euros, Abionyx Pharma, with the arrival last January of Dr Rob Scott as CMO and head of R&D, favors the search for a partnership strategic.
AOF – LEARN MORE
Learn more about the Pharmacy sector
Oncology, priority of pharmaceutical giants
Sanofi’s stock market disappointment recorded at the end of October 2023 underlines the new direction for the group, which has now set oncology as its number 1 priority. Efforts in this segment, where therapies are advancing the fastest, notably involve investments in R&D which weigh on profitability. Sanofi therefore announced a drop in its earnings per share in 2024 and the abandonment of its objective of an operating margin of 32% in 2025. Merck has just unveiled a new alliance. It will pay up to $22 billion to the Japanese group Daiichi Sankyo as part of a partnership on experimental cancer treatments. While some experts estimate that the United States represents nearly half of global oncology spending (drugs and treatments), or $196 billion in 2022, Chinese spending in this area has more than doubled in five years, going from 5 to 11.8 billion dollars.